Matthew G Annis

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Topics

Transforming Growth Factor

Squamous Cell Carcinoma

Top Venues

Proceedings of the National Academy of Sciences of the United States of America

Communications biology

Cancer research

This page only lists publications with an associated author ORCID identifier.

Publications

John J Heath, Caitlynn Mirabelli, Matthew G Annis, Valerie Sabourin, Steven Hébert, Steven Findlay, HaEun Kim, Michael Witcher, Claudia L Kleinman, Peter M Siegel, Alexandre Orthwein, Josie Ursini-Siegel
The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple Negative Breast Cancer by Attenuating TGFβ Signaling. Cancer research (2024)
Regina Cencic, Young K Im, Sai Kiran Naineni, Mohamed Moustafa-Kamal, Predrag Jovanovic, Valerie Sabourin, Matthew G Annis, Francis Robert, T Martin Schmeing, Antonis E Koromilas, Marilène Paquet, Jose G Teodoro, Sidong Huang, Peter M Siegel, Ivan Topisirovic, Josie Ursini-Siegel, Jerry Pelletier
A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America 121 (4) (2024)
Regina Cencic, Young K Im, Sai Kiran Naineni, Mohamed Moustafa-Kamal, Predrag Jovanovic, Valerie Sabourin, Matthew G Annis, Francis Robert, T Martin Schmeing, Antonis E Koromilas, Marilène Paquet, Jose G Teodoro, Sidong Huang, Peter M Siegel, Ivan Topisirovic, Josie Ursini-Siegel, Jerry Pelletier
A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America 121 (4) (2024)
Sébastien Tabariès, Alma Robert, Anne Marcil, Binbing Ling, Mauro Acchione, Julie Lippens, Martine Pagé, Annie Fortin, Luc Meury, Mathieu Coutu, Matthew G Annis, Charlotte Girondel, Julie Navarre, Maria L Jaramillo, Anna N Moraitis, Peter M Siegel
Anti-Claudin-2 Antibody-Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis. Molecular cancer therapeutics (2024)
Regina Cencic, Young K Im, Sai Kiran Naineni, Mohamed Moustafa-Kamal, Predrag Jovanovic, Valerie Sabourin, Matthew G Annis, Francis Robert, T Martin Schmeing, Antonis E Koromilas, Marilène Paquet, Jose G Teodoro, Sidong Huang, Peter M Siegel, Ivan Topisirovic, Josie Ursini-Siegel, Jerry Pelletier
A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America 121 (4) (2024)
Shawn McGuirk, Yannick Audet-Delage, Matthew G Annis, Yibo Xue, Mathieu Vernier, Kaiqiong Zhao, Catherine St-Louis, Lucía Minarrieta, David A Patten, Geneviève Morin, Celia M T Greenwood, Vincent Giguère, Sidong Huang, Peter M Siegel, Julie St-Pierre
Resistance to different anthracycline chemotherapeutics elicits distinct and actionable primary metabolic dependencies in breast cancer. eLife 10 (2021)
Sébastien Tabariès, Matthew G Annis, Anthoula Lazaris, Stephanie K Petrillo, Jennifer Huxham, Amri Abdellatif, Vincent Palmieri, Jaclyn Chabot, Radia M Johnson, Steven Van Laere, Cornelis Verhoef, Yasmina Hachem, Sara Yumeen, Nicholas Meti, Atilla Omeroglu, Gulbeyaz Altinel, Zu-Hua Gao, Alan S L Yu, Dirk J van Grünhagen, Peter Vermeulen, Peter Metrakos, Peter M Siegel
Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the replacement type growth pattern. Communications biology 4 (1) (2021)
Paul Savage, Alain Pacis, Hellen Kuasne, Leah Liu, Daniel Lai, Adrian Wan, Matthew Dankner, Constanza Martinez, Valentina Muñoz-Ramos, Virginie Pilon, Anie Monast, Hong Zhao, Margarita Souleimanova, Matthew G Annis, Adriana Aguilar-Mahecha, Josiane Lafleur, Nicholas R Bertos, Jamil Asselah, Nathaniel Bouganim, Kevin Petrecca, Peter M Siegel, Atilla Omeroglu, Sohrab P Shah, Samuel A J R Aparicio, Mark Basik, Sarkis Meterissian, Morag Park
Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors. Communications biology 3 (1) (2020)